Dr. Andrew Young -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. Andrew Young, a General Surgery physician based in City, CO. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Andrew Young has received $14,090.29 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. Andrew Young
- Medical Specialty: General Surgery
- Practice Location: City, CO, Colorado
- NPI Number: 1133175369
- Transparency Score: 50/100
- Payment Records Span: 2024-06-01 to 2024-06-01
Payment Summary
Dr. Andrew Young has received a total of $14,090.29 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $14,090.29 per transaction.
- Total Payments Received: $14,090.29
- Number of Transactions: 1
- Average Payment: $14,090.29
- Transparency Score: 50/100 -- This score reflects the overall payment profile relative to peers in General Surgery. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
- Drugs/Devices Referenced: 1 distinct products
Payment Breakdown by Category
The following table shows how Dr. Andrew Young's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Consulting Fees | $14,090.29 | Advisory board participation, clinical consulting, and expert opinion services |
The largest payment category for Dr. Andrew Young is Consulting Fees, accounting for 100% ($14,090.29) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. Andrew Young. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| Johnson & Johnson | $14,090.29 | 1 |
Dr. Andrew Young has a financial relationship with Johnson & Johnson, receiving $14,090.29 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
Drugs and Medical Devices Referenced in Payments
The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Andrew Young. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.
- Skyrizi -- Referenced in payment records from pharmaceutical companies to Dr. Andrew Young
The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. Andrew Young's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Dr. Andrew Young, a General Surgeon in City, CO, has received a total of $14,090.29 in pharmaceutical payments, stemming from a single transaction. This payment was made by Johnson & Johnson on June 1, 2024, and was categorized as consulting. When compared to the average payment volume for General Surgeons, Dr. Young's total payment volume is significantly lower. The average General Surgeon typically receives payments that can range from a few hundred dollars to tens of thousands annually, often spread across multiple companies and payment types. Dr. Young's profile, with a single, substantial payment from one company, stands out. The sole relationship identified is with Johnson & Johnson, which accounts for the entirety of the reported payments. This suggests a focused engagement with this particular pharmaceutical entity. The payment type is exclusively consulting, indicating a professional service rendered. This pattern, while involving a notable sum, does not inherently suggest routine professional activity in the same way that numerous small payments for meals or speaking engagements might. A single, larger consulting fee can be for a specific project or advisory role. However, the concentration of the entire payment volume from one company warrants a neutral observation, as it could represent a legitimate, albeit singular, professional engagement. For patient care, it's important to understand that pharmaceutical companies engage with physicians for various reasons, including education, research, and product development. Consulting fees, like the one received by Dr. Young, can be for providing expert opinions or participating in advisory boards. While these relationships can foster innovation and provide valuable insights, patients should be aware that such financial ties exist. Transparency in these relationships allows patients to have a more complete picture of potential influences on medical advice and treatment recommendations. Patients should know that while financial relationships between doctors and pharmaceutical companies are common, they are subject to disclosure. The key is understanding the nature and extent of these relationships. Dr. Young's single, disclosed payment from Johnson & Johnson is a piece of information that, when viewed alongside his overall practice, can contribute to a patient's understanding of their healthcare provider. It is crucial to consider this information in conjunction with the doctor's overall quality of care, patient reviews, and personal interactions.
Patient Guidance: Questions to Ask Your Doctor
If Dr. Andrew Young is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
When considering your doctor's financial relationships with pharmaceutical companies, it's helpful to approach the information with a balanced perspective. These relationships can serve legitimate purposes, such as advancing medical knowledge or improving treatments. However, awareness is key. At your next appointment, you might consider asking your doctor about their involvement with pharmaceutical companies, if you feel it's relevant to your care. For example, you could ask, 'Are there any new treatments or medications that you're particularly excited about, and have you had any involvement in their development or testing?' Red flags might include a doctor who seems overly enthusiastic about a specific drug without clear clinical justification, or who consistently prescribes a particular brand-name medication when a generic alternative is available and equally effective, especially if they have a known financial tie to that drug's manufacturer. It's important to remember that not all pharmaceutical relationships are concerning. Consulting for research or participating in advisory boards can be valuable. However, if a doctor's payments are extensive, concentrated with one company, or primarily consist of meals and entertainment rather than substantive professional activities like research or consulting, it might warrant closer scrutiny. Evaluate your doctor's prescribing patterns by looking at whether they favor newer, more expensive drugs without a clear clinical advantage over older, cheaper ones. Discussing treatment options openly and understanding the rationale behind prescribing decisions are crucial steps in managing your healthcare.
Peer Comparison: How Dr. Andrew Young Compares to Other General Surgery Physicians
Dr. Young's total pharmaceutical payment of $14,090.29 from a single source is considerably lower than the average annual payment received by many General Surgeons, which can often range from a few thousand to tens of thousands of dollars spread across multiple companies and payment types. While some surgeons may have no payments, others engage in more frequent, smaller transactions for speaking or meals. Dr. Young's profile, with one significant consulting fee, is less typical than a pattern of smaller, more frequent payments.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. Andrew Young in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| Johnson & Johnson | $14,090.29 | consulting | Skyrizi | 2024-06-01 | Not Assessed |
Frequently Asked Questions About Dr. Andrew Young's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
Is Dr. Andrew Young taking too much pharma money?
Dr. Young has received a single payment of $14,090.29 for consulting from Johnson & Johnson. Compared to the broader landscape of General Surgery, where payments can vary widely, this single transaction is not exceptionally high in absolute terms, but its concentration from one company is notable. Without more data on his overall practice and the typical engagement levels within his specific sub-specialty, it's difficult to definitively label it 'too much.' The key is the nature of the consulting work and whether it aligns with ethical guidelines and patient best interests.
What pharma companies pay Dr. Andrew Young?
Dr. Andrew Young receives payments exclusively from Johnson & Johnson, totaling $14,090.29. This represents his entire reported pharmaceutical payment history.
Should I switch doctors because of pharma payments?
A single payment, even a substantial one, is not typically a reason to switch doctors. Consider the context: was it for legitimate consulting or research? Does your doctor openly discuss treatment options and alternatives? If you have concerns about your doctor's prescribing habits, communication, or overall care, then exploring other options might be appropriate, but financial disclosures alone are rarely sufficient cause.
What kinds of payments does this doctor receive?
Dr. Young has received one payment totaling $14,090.29, which was specifically for consulting services provided to Johnson & Johnson.
How do these payments compare to other General Surgery?
Dr. Young's total payment of $14,090.29 from a single source is less than the average annual payments received by many General Surgeons, which can often be higher and spread across multiple companies and payment types like speaking fees or research grants. His profile is characterized by a single, significant consulting fee rather than numerous smaller transactions.
Do pharma payments affect prescribing quality?
Research suggests that even small payments can influence physician prescribing habits, often subtly. While financial relationships can foster innovation and education, they also create potential for bias. Patients should be aware that these payments exist and discuss treatment options openly with their doctors, ensuring decisions are based on clinical evidence and individual patient needs, not solely on promotional activities.
How can I verify this payment data?
You can verify this payment data directly through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. Visit the official CMS Open Payments website, search for 'Andrew Young' and his NPI '1133175369', and review the disclosed payment records for accuracy.
Understanding This Doctor Payment Report
This transparency report for Dr. Andrew Young is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. General Surgery physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. Andrew Young's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. Andrew Young and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- General Surgery Specialty Payment Data -- See payment patterns for all general surgery physicians
- Colorado Physician Payments -- Browse pharmaceutical payments to physicians in Colorado
- General Surgery Physicians in Colorado -- Compare Dr. Andrew Young to peers in the same state and specialty
- Johnson & Johnson Payment Profile -- View all payments made by Dr. Andrew Young's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. Andrew Young's NPI (1133175369) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.